Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-NMMA and Taxane for Refractory TNBC
NCT02834403Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Nov 2016
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of NG-monomethyl-L-arginine in triple-negative breast cancer (TNBC), sponsored by Houston Methodist Research Institute. Started Nov 2016; status: completed.
02
Drugs
NG-monomethyl-L-arginine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02834403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834403.